Nvidia's Plan to Dominate the World of Robotics ...
Robots just had a coming-out party in Las Vegas. From household helpers to rescue bots, they're now essential-not just novelties. Forbes says it's a $24T opportunity. And Nvidia's CEO says one $7 stock is key to building the world's first trillion-dollar robot.
FDA's Prasad Cites Alleged Child COVID Shot Deaths in Push for Stricter Rules
FDA's new vaccine strategy tightens approval rules after internal findings linked COVID-19 shots to several child deaths.
Analyst Sees Strong Medtronic Momentum Through 2026 With Buy Rating Intact
BofA expects Medtronic to post over 5% second-quarter revenue growth and maintain strong momentum through 2026, driven by robust procedure trends.
Gold Alert: Extraordinary Upside in One Stock (Not a Miner) - Ad
Gold has hit all-time highs, breaking $4,000 an ounce - but history shows it could be on the verge of its biggest bull run in over half a century... triggered by a likely major event, eerily similar to what happened in the 1970s. (It's NOT inflation or anything you're likely expecting.) Now, a top analyst says you can capture ALL of the upside without touching a risky miner or a boring exchange-traded fund. He sees extraordinary potential gains long term with very little risk.
Why Is Scholar Rock Holding Stock Climbing Today?
Scholar Rock shares jump after the company strengthened its cash runway into 2027 and advanced launch preparations for its lead drug candidate, apitegromab.
Biogen, Eisai File In Japan To Make Leqembi A Weekly At-Home Alzheimer's Shot
Eisai files for Japan approval of a weekly at-home Leqembi injection, offering an alternative to IV dosing and aiming to streamline Alzheimer's care.
Copper Is Tight, Silver Is Rising - And This Early Nevada Play Hits the Timing Perfectly - Ad
AI, electrification, battery storage, and data centers are pushing copper and silver demand sharply higher, even as supply stays tight. This region in Nevada offers rare multi-metal potential, and a new company has secured land in a district the surging district. It's one of the cleanest timing setups in the sector right now.
Baxter Warns Of Potential Device Tampering In Life2000 Ventilator Recall
Baxter recalls its Life2000 ventilators after a cybersecurity flaw prompts an FDA high-risk alert, urging patients to stop use and seek replacement options.
BiomX Awaits FDA Clearance To Restart Cystic Fibrosis Trial After Nebulizer Device Review
BiomX works to address FDA device questions as a safety panel supports the BX004 trial, with topline results now expected in Q2 2026.
First Drug to Show Breakthrough Myocarditis Data. Analysts See Potential 7-10x Upside. - Ad
This biotech just delivered a medical first in myocarditis and has a Phase 3 trial fully funded into 2027. Wall Street targets imply massive revaluation ahead.
Sanofi Faces Surprise HQ Search As French Authorities Expand Tax Probe
Sanofi faces a surprise tax probe in France as Dupixent secures EU approval for treating chronic spontaneous urticaria.
Novo Nordisk Alzheimer's Miss Disappointing But Not Material, Analyst Says
Novo Nordisk stock falls after disappointing results from Alzheimer's trial. Analysts remain cautious about future growth prospects.
The Next 'Ozempic Moment' Could Be in Heart Disease - Ad
Just as Ozempic rewrote the obesity playbook, this breakthrough data could transform how we treat inflammatory heart disease. Fully funded. Multiple catalysts. $280B market opportunity.
Bayer Stroke Drug Hits Trial Goals, Analyst Sees Positive Data Readout From Bristol Myers' Milvexian After Failed Study
Bayer's asundexian cut ischemic stroke risk without more bleeding, boosting FXIa optimism while raising fresh questions for Bristol Myers' milvexian program.
Here's what's next in the fight to curb climate change, now that talks in Brazil have ended
BELEM, Brazil (AP) — After from U.N. climate talks in the Amazon that fell short of many nations' expectations, experts found some bright spots alongside weighty reasons for worry in the fight against .
Urgent Copper Stock With Strong Catalysts - Ad
Quebec discovery. Strong grades. Roads and hydro in place. Funding secured for a busy drill calendar. Each assay can build scale and tighten the window for early entries as EVs and data centers pull harder on copper. Do not wait.
Plan for $20 million firefighter training center near the site of Ohio derailment revived
Norfolk Southern railroad worked with the state of Ohio and Youngstown State University to revive plans for a $20 million first responder training center near the site of the in East Palestine, Ohio.
FDA Flags Antibody Risk After Child's Death Linked To Takeda's Enzyme Replacement Therapy For Rare Blood Disorder
FDA reports rare neutralizing antibodies, including a pediatric death, in patients treated with Takeda's Adzynma for congenital TTP.
Nvidia's Plan to Dominate the World of Robotics ... - Ad
Robots just had a coming-out party in Las Vegas. From household helpers to rescue bots, they're now essential-not just novelties. Forbes says it's a $24T opportunity. And Nvidia's CEO says one $7 stock is key to building the world's first trillion-dollar robot.
Vanda Reports Big Win In Wegovy Support Study, Analysts Upbeat
Vanda's tradipitant cut Wegovy-related vomiting by 50% in a new trial, prompting bullish analyst views and price targets.
Activist Investor Drops Scathing Letter, Slams Cooper's 'Growth At All Costs' Approach
Browning West urges changes for underperforming Cooper Companies, highlighting weak oversight and misaligned incentives.
Is Big Pharma's Next Target Already in Play? - Ad
A small biotech may have cracked one of medicine's biggest problems-how to deliver cancer drugs safely and effectively. With patented technology and promising early data, it's already catching the attention of Big Pharma.
As infant botulism cases climb to 31, recalled ByHeart baby formula is still on some store shelves
As cases of potentially deadly botulism in babies who drank ByHeart infant formula continue to grow, state officials say they are still finding the on some store shelves.
Guterres and Lula to push negotiators at COP30 as deadline looms
BELEM, Brazil (AP) — Two global power players will spend Wednesday pushing negotiators to find compromises at in Brazil’s Belém, where a self-imposed deadline is rushing up fast.
New Number One Copper Start Alert - Ad
EVs and AI devour copper. Supply cannot keep up. A Quebec discovery with high grade, infrastructure, and cheap power is funded to drill through the year. Catalysts are lining up. Institutions are circling. Move now while it is still early.
Major Victory For Genmab As Epkinly Receives FDA Approval For Type Of Pretreated Blood Cancer
Genmab's Epkinly receives traditional FDA approval for relapsed or refractory follicular lymphoma in combination and monotherapy. Clinical trial data show superior results.
Judge to explain why he's approving Purdue Pharma settlement plan, which calls for $7B from Sacklers
A U.S. Bankruptcy Court judge is set to give his reasoning Tuesday for approving OxyContin maker Purdue Pharma's plan to settle thousands of lawsuits over the toll of opioids.
Nevada's Mining Renaissance Is Accelerating - And This Early Opportunity Is Well Positioned - Ad
Nevada's Walker Lane belt has produced 50M+ ounces of gold since the 1800s, and it's waking up again. One of the neighborhood's latest successes just secured over $6M in U.S. support and is up more than 300% YTD. Now a new early-stage explorer has moved in next door.
AP Lifestyles Digest for week of Nov. 17
Here is the AP Lifestyles Digest for the week of Nov. 17. Note AP's Holiday Gift Guide Digest moved Nov. 12 and is included at the end.
As nations push for more ambition at climate talks, chairman says they may get it
BELEM, Brazil (AP) — Going into , the Brazilian hosts weren’t looking for big end-of-session pronouncements on lofty goals. This conference was supposed to hyperfocus on “implementation” of .
A Tiny Biotech Just Posted 10× Stronger Cancer Results - Ad
Early studies show this breakthrough delivery platform would make cancer treatments safer and more powerful. Now, with Big Pharma watching closely, investors are starting to take notice of what could be the next major biotech story.
Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus
Cartesian Therapeutics shared initial data from Phase 2 trial of Descartes-08, showing potential for treating systemic lupus erythematosus.
Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial
Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.
Gold Alert: Extraordinary Upside in One Stock (Not a Miner) - Ad
Gold has hit all-time highs, breaking $4,000 an ounce - but history shows it could be on the verge of its biggest bull run in over half a century... triggered by a likely major event, eerily similar to what happened in the 1970s. (It's NOT inflation or anything you're likely expecting.) Now, a top analyst says you can capture ALL of the upside without touching a risky miner or a boring exchange-traded fund. He sees extraordinary potential gains long term with very little risk.
Workers take on side jobs to combat stagnant salaries and insecurity about employment
NEW YORK (AP) — As workers face , inflation and , some have decided to branch out from their traditional careers. They're taking on side jobs to bring in additional income and provide a backup plan should they , or adding second, third and sometimes fourth jobs — what some call “polyworking” — to the mix.
Federal workers question whether the longest government shutdown was worth their sacrifice
WASHINGTON (AP) — Jessica Sweet spent cutting back. To make ends meet, the Social Security claims specialist drank only one coffee a day, skipped meals, cut down on groceries and deferred paying some household bills. She racked up spending on her credit card buying gas to get to work.
Copper Is Tight, Silver Is Rising - And This Early Nevada Play Hits the Timing Perfectly - Ad
AI, electrification, battery storage, and data centers are pushing copper and silver demand sharply higher, even as supply stays tight. This region in Nevada offers rare multi-metal potential, and a new company has secured land in a district the surging district. It's one of the cleanest timing setups in the sector right now.
This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power
Apellis reports five-year Syfovre data showing up to 31% slower GA lesion growth, reinforcing strong long-term efficacy and analyst optimism.
More than 80 nonprofits receive $250M for global women's health from Melinda French Gates
More than 80 organizations that provide health care for women all over the world received grants Wednesday totaling after a year-long application process.
Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.